Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of blood cancer called diffuse large B-cell lymphoma (DLBCL), confirmed through laboratory testing of tissue samples
- People who have received exactly two prior standard treatment courses for DLBCL, which must have included an anti-CD20 antibody therapy and a chemotherapy-type treatment
- People whose cancer did not respond to their most recent treatment, or whose cancer has come back or worsened after their most recent treatment
- People who have at least one measurable area of cancer that can be seen on a scan
- People who have a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out at least some daily activities) (confirm with trial site)
- People whose blood counts and liver and kidney function meet specific levels as defined by the trial (confirm with trial site)
Who may not be able to join:
- People whose lymphoma started in or has spread to the brain or spinal cord, or who have certain other specific subtypes of lymphoma, including transformed lymphoma, primary effusion lymphoma, or plasma lymphoma
- People who are still experiencing side effects from previous cancer treatments that have not yet resolved
- People who have an active infection that is not under control, or who need antibiotic treatment given through a drip
- People who have received certain treatments — including steroids, chemotherapy, targeted therapy, radiation, or antibody-based therapy — within a recent period specified by the trial (confirm with trial site for exact timeframes)
- People who are unable to swallow tablets, or who have significant digestive system problems that may affect how the study drug is absorbed
- People who have had a stem cell transplant (either their own cells or a donor's cells) within a timeframe specified by the trial (confirm with trial site)
- People who have an active graft-versus-host reaction (a complication that can occur after a donor stem cell transplant)
- People who have had a major surgical procedure within the last month
- People with evidence of HIV or hepatitis C virus infection
- People with certain heart conditions as defined by the trial (confirm with trial site)
- People who have a history of any other cancer besides DLBCL
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yuankai SHI, Prof, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phone: (01186)13716386801
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical effect by evaluating the objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.